Omadacycline is a novel tetracycline antibiotic, with intravenous and oral formulations. It has a broad-spectrum and high efficiency, and is resistant to bacterial resistance due to drug efflux and ribosome protection mechanisms, with potent activity against various pathogens,such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae, extended-spectrum beta-lactamase (ESBL)-producing gram-negative bacteria, anaerobes, and atypical pathogens. Omadacycline is currently approved for the treatment of acute bacterial skin and soft tissue infection as well as community-acquired bacterial pneumonia in adults, it can also be used to treat uncomplicated urinary tract infection. This paper summarized the chemical structure, pharmacological effect, in vitro antibacterial activity, pharmacokinetics, clinical study, safety, and tolerability of omadacycline.